January 25, 2023 (Source) – Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (“Valeo” or the “Company“), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the fourth quarter and year ended October 31, 2022 on Monday January 30, 2023 after market close. The Company will host a conference call to discuss those results and highlights on Tuesday January 31, 2023 at 8.30am (ET).
To join the conference call without operator assistance, you may register and enter your phone number at https://bit.ly/3XlAGpn to receive an instant automated call back.
You can also dial direct to be entered to the call by an Operator. (Traditional conference call instructions here):
|Date:||Tuesday, January 31, 2023|
|Dial-in numbers:||1-888-664-6392 or 416-764-8659|
|Audio replay numbers:||1-888-390-0541 or 416-764-8677|
|Replay code:||880970 #|
|A live audio webcast of the conference call will be available via:|
About Valeo Pharma Inc.
Valeo Pharma is a fast growing Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory/Allergy, Ophthalmology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter.
Forward Looking Statements
This press release contains forward-looking statements about Valeo’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.
SOURCE Valeo Pharma Inc.
For further information: Steve Saviuk, CEO, 514-693-8830, email@example.com or Luc Mainville, Senior Vice-President and Chief Financial Officer, 514-693-8854, firstname.lastname@example.org or Frederic Dumais, Director, Communications and Investor Relations, 514-693-8847, email@example.com